Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)

Synchronous tumors are defined as two tumors arising concurrently or within six months of each other. Reports of synchronous RCC and breast cancer are limited to nonmetastatic renal cell carcinoma (RCC) and hormone receptor-positive infiltrative ductal carcinoma. We present the first case of synchro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Iris Y., Kruse, Megan, Leininger, Kathryn M., Ornstein, Moshe C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589247/
https://www.ncbi.nlm.nih.gov/pubmed/31281697
http://dx.doi.org/10.1155/2019/6246209
_version_ 1783429362724372480
author Sheng, Iris Y.
Kruse, Megan
Leininger, Kathryn M.
Ornstein, Moshe C.
author_facet Sheng, Iris Y.
Kruse, Megan
Leininger, Kathryn M.
Ornstein, Moshe C.
author_sort Sheng, Iris Y.
collection PubMed
description Synchronous tumors are defined as two tumors arising concurrently or within six months of each other. Reports of synchronous RCC and breast cancer are limited to nonmetastatic renal cell carcinoma (RCC) and hormone receptor-positive infiltrative ductal carcinoma. We present the first case of synchronous metastatic renal cell carcinoma and metastatic triple-negative breast cancer, managed with a novel combination of immunotherapy and chemotherapy.
format Online
Article
Text
id pubmed-6589247
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65892472019-07-07 Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC) Sheng, Iris Y. Kruse, Megan Leininger, Kathryn M. Ornstein, Moshe C. Case Rep Oncol Med Case Report Synchronous tumors are defined as two tumors arising concurrently or within six months of each other. Reports of synchronous RCC and breast cancer are limited to nonmetastatic renal cell carcinoma (RCC) and hormone receptor-positive infiltrative ductal carcinoma. We present the first case of synchronous metastatic renal cell carcinoma and metastatic triple-negative breast cancer, managed with a novel combination of immunotherapy and chemotherapy. Hindawi 2019-06-04 /pmc/articles/PMC6589247/ /pubmed/31281697 http://dx.doi.org/10.1155/2019/6246209 Text en Copyright © 2019 Iris Y. Sheng et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sheng, Iris Y.
Kruse, Megan
Leininger, Kathryn M.
Ornstein, Moshe C.
Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
title Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
title_full Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
title_fullStr Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
title_full_unstemmed Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
title_short Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
title_sort tailoring immunotherapy treatment of synchronous renal cell carcinoma (rcc) and triple-negative breast cancer (tnbc)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589247/
https://www.ncbi.nlm.nih.gov/pubmed/31281697
http://dx.doi.org/10.1155/2019/6246209
work_keys_str_mv AT shengirisy tailoringimmunotherapytreatmentofsynchronousrenalcellcarcinomarccandtriplenegativebreastcancertnbc
AT krusemegan tailoringimmunotherapytreatmentofsynchronousrenalcellcarcinomarccandtriplenegativebreastcancertnbc
AT leiningerkathrynm tailoringimmunotherapytreatmentofsynchronousrenalcellcarcinomarccandtriplenegativebreastcancertnbc
AT ornsteinmoshec tailoringimmunotherapytreatmentofsynchronousrenalcellcarcinomarccandtriplenegativebreastcancertnbc

Ejemplares similares